Visgenx
Visgenx develops gene-based retinal therapies to combat vision loss from retinal disorders.
Founded
2018Visgenx develops gene-based retinal therapies to combat vision loss from retinal disorders.
Visgenx was founded with the mission to develop gene-based therapies aimed at combating vision loss caused by retinal disorders. The company's core focus is on increasing the expression of the ELOVL2 gene, which has been shown to play a role in regulating aging in retinal cells. Their primary product targets Dry Age-related Macular Degeneration (Dry-AMD), a progressive disease that leads to the loss of photoreceptor cells and visual acuity. Visgenx aims to bring innovative solutions to the market that can significantly improve the quality of life for individuals suffering from degenerative retinal diseases.
Notable figures affiliated with Visgenx include leading scientists and researchers in the field of ophthalmology and gene therapy. The company has garnered attention and support from key investors interested in advancing medical treatments for vision impairment. Among its key achievements, Visgenx has made significant strides in preclinical trials, demonstrating the potential efficacy of their ELOVL2 gene therapy. The overall impact of Visgenx lies in its potential to revolutionize the treatment landscape for retinal disorders, offering hope to millions of patients worldwide who are at risk of losing their sight.
Companies similar to Visgenx include Oculogenex, ReVision Therapeutics, Visible Genomics and Visiox.
Visgenx was founded in 2018.
Visgenx's headquarters is located in San Diego, CA, US.
Visgenx's most recent funding round was for $2.8M (USD) in June 2023.
As of Jun 14, 2023, Visgenx has disclosed funding of $8.5M (USD). Undisclosed round amounts are excluded.
Visgenx has 5 employees as of Feb 5, 2024.
Visiox
visioxpharma.com
